NDAOPHTHALMICSUSPENSION/DROPS
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
7/8 — Comprehensive
INVELTYS (loteprednol etabonate) by Alcon is healing. Approved for inflammation, pain, ocular inflammation and 1 more indications. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INVELTYS (loteprednol etabonate) is a topical ophthalmic corticosteroid suspension approved in 2018 for treating ocular inflammation and pain across multiple indications including allergic conjunctivitis, post-operative inflammation, and macular edema. It works by inhibiting prostaglandin production and suppressing inflammatory cascades including edema, fibrin deposition, and leukocyte migration in the eye. The formulation provides targeted anti-inflammatory activity with a favorable corticosteroid safety profile for ocular use.
$0.003BPart D
Peak7.0 years to LOEProduct is at peak lifecycle stage with modest Part D utilization; team size likely stable with focus on maintaining market position against emerging competitors.
Mechanism of Action
healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid…
Indications (4)
Worked on INVELTYS at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.